Table 4.
Outcomes by HRR status, data for experimental assays and Myriad test
| Myriad |
LAB1 |
LAB2 |
LAB3 |
|||||
|---|---|---|---|---|---|---|---|---|
| HRD | HRP | HRD | HRP | HRD | HRP | HRD | HRP | |
| Eligible for RECIST assessment | 59 | 63 | 62 | 47 | ||||
| Response rate (95% CI) | 82.4% (64.8% to 92.2%) | 60% (38.8% to 78.0%) | 84.2% (68.1% to 93.0%) | 56.0% (35.3% to 74.8%) | 75.8% (57.4% to 87.9%) | 65.5% (45.7% to 81.0%) | 90.9% (46.3% to 99.1%) | 72.2 (54.7% to 84.8%) |
| Eligible for survival analysis | 94 | 97 | 97 | 69 | ||||
| Median PFS (months) (95% CI) | 18.6 (12.0-22.3) | 20.2 (17.0-25.3) | 19.8 (16.3-24.2) | 18.6 (12.0-22.6) | 20.8 (16.3-27.5) | 17.7 (12.0-22.1) | 19.2 (15.8-22.1) | 17.7 (9.9-25.1) |
| Median OS (months) (95% CI) | 40.6 (27.3-NE) | 41.1 (34.8-NE) | 61 (37.9-NE) | 39.7 (24.7-NE) | 41.1 (34.8-42.0) | 39.7 (24.7-NE) | 37.9 (27.2-NE) | 39.7 (17.9-NE) |
HRD, homologous recombination deficiency; HRP, homologous recombination proficiency; HRR, homologous recombination repair; LAB, laboratory; NE, not estimated; PFS, progression-free survival; OS, overall survival.